Clinical endpoints in Duchenne muscular dystrophy (DMD) rely on motivation-dependant assessments performed in the clinic, which may not reflect disease and therapy impact on every-day life functionality, which in turn is a more accurate reflection of impact on quality of life. In the KineDMD study, we pursue a patient-centric approach to obtain a complete data-driven picture of full-body behavioural capacity in real-life over a 12 month period. Our Ethomics approach (Ethology & Omics) has 2 sides: "At home" & "In clinic". In the "At home" side, we monitor patients behaviour on a 24/7 basis using four sensors Etho4 on the four extremities to obtain a dense, continuous understanding of their motor activities and capabilities. DMD boys and age-matched healthy boys (HC) consented to wear a Etho-4s set consisting of 4 smart sensors ('watches') tracking each wrist and ankle in 6 Degrees of Freedom (accelerometer and gyroscope readings each along the three axes). In addition to wearing the sensors in the clinic during physiotherapy assessment, they are also worn in and outside of the home all day long, occasionally also at night. Movement data are collected continuously and in high temporal resolution, and sent daily to our servers through a user-friendly computer interface. In this on-going pilot study, we observed high compliance of the boys. The DMD boys wore the sensors approximately 62% of days since recruitment, for an average of 10 hours/day. On initial inspection of the data, we observed that real-life limb acceleration variability in DMD is significantly restricted across all 4 limbs. Furthermore, initial analysis confirmed that the degree of movement correlation during a day of a DMD boy compared to HC shows clear signatures of DMD kinematics. Using simple machine learning classifier operating on movement variability, it was possible to clearly distinguish DMD disease state from HC with >80% accuracy using the Etho-4s alone. These preliminary results support that real-life kinematics captured by our Etho-4s are collectable with high patient compliance across real-life activities. Furthermore, real-life activity yields clear disease signatures in DMD. While sensors are a stepping stone, key efforts are focused on appropriate behaviour analytics technology to develop potential novel clinical endpoints based on real-life patients' activities.